[Trend of research and development of antihypertensive agents].
Imura
Yoshimi
Y
Pharmacology Research Laboratories I, Takeda Pharmaceutical Company Ltd.
D000577:Amides; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000809:Angiotensins / Q000276:immunology; D000959:Antihypertensive Agents / Q000627:therapeutic use; D016282:Aspartic Acid Endopeptidases / Q000037:antagonists & inhibitors; D001562:Benzimidazoles / Q000627:therapeutic use; D001713:Biphenyl Compounds; D004338:Drug Combinations; D015195:Drug Design; D065128:Endothelin Receptor Antagonists; D000072396:Endothelin-Converting Enzymes; D005650:Fumarates / Q000627:therapeutic use; D006801:Humans; D006973:Hypertension / Q000628:therapy*; D016233:Immunotherapy, Active; D008666:Metalloendopeptidases / Q000037:antagonists & inhibitors; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use; D010666:Phenylpropionates / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D013777:Tetrazoles / Q000627:therapeutic use; D000092502:Renin Inhibitors
D000577:Amides; D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000809:Angiotensins; D000959:Antihypertensive Agents; D016282:Aspartic Acid Endopeptidases; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D004338:Drug Combinations; D065128:Endothelin Receptor Antagonists; D000072396:Endothelin-Converting Enzymes; D005650:Fumarates; D008666:Metalloendopeptidases; D000451:Mineralocorticoid Receptor Antagonists; D010666:Phenylpropionates; D011743:Pyrimidines; D013777:Tetrazoles; D000092502:Renin Inhibitors; C107831:darusentan; C446481:aliskiren; C081643:candesartan